Delving into the Latest Updates on Cambium Medical Technologies LLC with Synapse

概览

关联

1

项与 Cambium Medical Technologies LLC 相关的药物

CAM-101

靶点-

作用机制

细胞替代物

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

1

项与 Cambium Medical Technologies LLC 相关的临床试验

NCT03414645

/ Completed临床1/2期

Randomized Multicenter Double-Masked Placebo-Controlled Parallel Phase I/II Study to Determine the Safety and Exploratory Efficacy of Topical Fibrinogen Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs Host Disease

The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye drops in patients with Dry Eye Disease (DED) secondary to Graft vs. Host Disease (GvHD).

开始日期2018-05-01

申办/合作机构

Cambium Medical Technologies LLC

[+6]

100 项与 Cambium Medical Technologies LLC 相关的临床结果

登录后查看更多信息

0 项与 Cambium Medical Technologies LLC 相关的专利（医药）

登录后查看更多信息

100 项与 Cambium Medical Technologies LLC 相关的药物交易

登录后查看更多信息

100 项与 Cambium Medical Technologies LLC 相关的转化医学

登录后查看更多信息